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Results: A total of 35% (139/397) of pharmacists responded to the survey, and 57% of these had APA. Depending on the case scenario, 55% to 92% of pharmacists correctly identified patients eligible for stroke prevention therapy, but only about a half selected the appropriate antithrombotic agent; there was no difference in the knowledge according to APA status. In multivariable analysis, predictors significantly associated with guidelineconcordant prescribing were having the pharmacist interact as part of an interprofessional team (p = 0.04) and direct OAc (DOAc) self-efficacy (confidence in ability to extend, adapt, initiate or alter prescriptions; p = 0.02). barriers to prescribing OAc for APA pharmacists included a lack of AF and DOAc knowledge and preference for consulting the physician first, but these same pharmacists also identified difficulty in contacting the physician as a major barrier.
Despite robust evidence that oral anticoagulation therapy is effective and safe for stroke prevention in patients with atrial fibrillation (AF), there is a lack of real-world application. The public health consequences of undertreated AF are enormous; thus, exploring alternative strategies to deliver stroke prevention therapy is needed.
Alors qu'il existe de solides données attestant de l'efficacité et de l'innocuité de l'anticoagulothérapie orale pour la prévention des accidents vasculaires cérébraux (AVC) chez les patients atteints de fibrillation auriculaire (FA), on possède peu d'information en situation réelle. En raison des conséquences désas-treuses d'un traitement inadéquat de la FA pour la santé publique, il est nécessaire d'explorer d'autres stratégies pour la prestation des traitements

Introduction
Atrial fibrillation (AF) is the most common arrhythmia 1 and the leading cause of stroke. 2 AF-related strokes are associated with significant morbidity 2 and mortality, 3, 4 and costs are considerable, approximately $3.6 billion annually in Canada. 5 Despite robust evidence that oral anticoagulation (OAC) therapy is effective and safe in preventing stroke, 6, 7 and the availability of simple risk schema and guidelines providing strong recommendations [8] [9] [10] on who would benefit from OAC, fewer than two-thirds of eligible patients are prescribed appropriate therapies. [11] [12] [13] The public health consequences of undertreated AF are enormous; thus, alternative strategies to deliver stroke prevention therapy, such as pharmacistdirected interventions, need to be explored. Pharmacist practices have been evolving over the past century, from medication dispensing to managing drug therapy and prescribing.
Original research
Since 2007, pharmacists in Alberta have had the opportunity to apply for additional prescribing authority (APA) after at least 1 year of full-time experience in direct patient care and demonstrating their ability to practise and document according to the Standards of Practice for Pharmacists and Pharmacy Technicians.
14 There are numerous studies demonstrating that pharmacist involvement in disease monitoring and optimization of drug therapies for cardiovascular risk factors and heart failure increases adherence to guideline-based targets and improves outcomes. [15] [16] [17] In meta-analyses, compared to usual care, pharmacist-directed care or pharmacist collaborative care with nurses or physicians was associated with significant reductions in systolic blood pressure, 18 low-density lipoprotein, 19 improved hemoglobin A1c 20 and reduced heart failure hospitalizations. 21 Pharmacist-led anticoagulation clinics for AF have been shown to improve adequacy of anticoagulation, patient satisfaction and quality of life. [22] [23] [24] In recent years, randomized clinical trials have shown that compared to warfarin, direct OAC (DOAC) therapies are easier to administer and reduce the risk of stroke/systemic embolism by 23%, total mortality by 11% and intracranial bleeding events by 54%. 7 The health care burden of stroke due to poor prophylaxis with antithrombotic therapy in AF demands capitalization on existing frameworks to improve patient outcomes. Given that we now have DOACs that should simplify care delivery (compared to warfarin) and pharmacists legislated to prescribe, we explored the potential for prescribing of antithrombotic therapy for AF by pharmacists, focusing on appropriateness of therapy and potential barriers to prescribing.
Methods
Study design
A cross-sectional Web-based survey of pharmacists in Alberta was conducted from February to March 2016.
Survey questionnaire
The survey questionnaire was constructed to explore community pharmacists' prescribing specific to the appropriateness of antithrombotic therapy (as per the 2014 Canadian Cardiovascular Society AF guidelines) and perceived barriers to care. 9 It was adapted from 2 prior surveys. 25, 26 The first explored pharmacists' prescribing habits in practice, and the second was a set of cases adapted to explore physicians' knowledge of DOACs in AF. The survey was reviewed by authors of this manuscript, including a physician who was a member of the guideline writing task force and pharmacists and physicians with expertise in AF research. A pharmacist independent from the study investigators completed the survey to provide feedback on the clarity of the questions. The survey included questions on demographics (sex, highest level of education, year of obtaining license, type of position, work status, APA status), practice characteristics (practice location, practice setting, access to electronic medical records [i.e., the Alberta-wide Netcare electronic record, which includes all laboratory tests, hospital discharge summaries, emergency room visit records and diagnostic imaging]), method of interaction with physicians, practice patterns for prescribing (self-efficacy defined as confidence in ability to extend, adapt, initiate or alter prescriptions), 4 clinical case scenarios (history, physical exam, labs and imaging) and questions to determine reasons for choosing DOAC or warfarin and to identify perceived barriers to prescribing OAC and contacting the patient's physician. Each of the 4 case scenarios asked if antithrombotic therapy should be initiated (yes or no) and which drug would be most appropriate (aspirin, warfarin, DOAC). We also asked
KnOwleDge IntO PrActIce
• Atrial fibrillation (AF) is the most common arrhythmia and the leading cause of stroke.
• AF-related strokes are associated with considerable morbidity and mortality, yet are highly preventable with oral anticoagulation (OAc) therapy.
• the emergence of direct oral anticoagulants (DOAcs) has made it easier, safer and more convenient to initiate OAc than warfarin.
• this study explores pharmacists' current knowledge of stroke prevention in AF and potential barriers to prescribing OAc therapy.
• the majority of pharmacists identified patients eligible for stroke prevention, but decisions regarding which drug therapy to use were lacking. Pharmacists recognized confidence in AF and DOAc knowledge as barriers to prescribing, and pharmacists preferred to contact a physician prior to OAc initiation.
• A strategy to address existing treatment gaps may be prescribing of stroke prevention therapy by community pharmacists, but this requires a framework for physician collaboration and appropriate training about guideline recommendations for OAc therapy.
Original research if the patient's physician would be contacted to initiate OAC if the pharmacists did not have APA status, as well as if pharmacists with APA status and an existing relationship with a patient would initiate OAC and, if the answer was "no, " whether the physician would be contacted to initiate therapy. The survey also captured practice location categorized by population, setting based on type of pharmacy practice and method of interaction with physicians.
Data collection
The survey was sent to 397 pharmacists, half with APA, randomly selected from a master list obtained through the Alberta College of Pharmacists using a computerized program. The Population Research Laboratory in the Department of Sociology at the University of Alberta sent a presurvey letter approximately 2 weeks prior to the email with the survey link containing information about the study and a $5.00 coffee card as appreciation of the pharmacist's time and consideration for participating in the study. This was followed by an email with a link to the online survey. Pharmacists received a reminder each week over the 6-week period.
Inclusion and exclusion criteria
Pharmacists included in the study had a practising license with the Alberta College of Pharmacists and had to reside in Alberta. Pharmacists who reported not having regular involvement in patient care in the prior 6 months of survey administration were excluded (n = 5), leaving 134 pharmacists for the analysis.
Consent and ethical consideration
This research project was approved by the University of Alberta Ethics Board. Participant consent was voluntary and online submission of the completed survey indicated consent. All data collected were anonymous and used in an aggregated format.
Statistical analysis
Descriptive statistics were used to report the frequencies, percentages, means and standard deviations for the survey responses. Categorical variables were compared using a chi-square test, and a t test was used for continuous variables with significance value of <0.05. A stepwise regression analysis was performed to identify predictors of knowledge, with entry criterion of p < 0.10 and stay criterion of p < 0.05. The predictors included in the model were highest level of education, practice location, practice setting, interaction with physicians (fax, phone/ face-to-face, interprofessional team), percentage of time involved in patient care services, percentage of time on medication preparatory activities, busyness, frequency of prescribing, warfarin selfefficacy and DOAC self-efficacy. Statistical analyses were performed using SAS v9.3 (SAS Institute, Cary, NC).
Results
Demographics and practice characteristics
A total of 35% (139/397) of pharmacists responded to the survey; of these, 57% had APA. Overall, 67% of the pharmacists were female, 82% had a bachelor's degree and the majority worked full-time (79%) at community pharmacies (71%, Table 1 ). Pharmacists with APA were more often in a manager/director or clinical practice leader role than pharmacists without APA (p = 0.03). All pharmacists had access to Netcare, and 81% used it "routinely" for reviewing lab values, over half for reviewing medical
MIse en PrAtIQUe Des cOnnAIssAnces
• la fibrillation auriculaire (FA) est la forme la plus fréquente d'arythmie et également la principale cause d'accident vasculaire cérébral (AVc).
• les AVc liés à la FA sont associés à une morbidité et à une mortalité considérables; ils sont pourtant hautement évitables grâce à l'anticoagulothérapie orale (AcO).
• l'arrivée des anticoagulants oraux directs (AcOD) a rendu l'AcO plus facile, plus sûre et plus pratique que l'AcO par la warfarine.
• la présente étude vise à évaluer les connaissances actuelles des pharmaciens sur la prévention de l'AVc en présence de FA et à examiner les obstacles potentiels à la prescription d'une AcO.
• la majorité des pharmaciens ont été en mesure de déterminer les patients admissibles à un traitement préventif de l'AVc, mais ont éprouvé des difficultés à choisir le traitement à utiliser. les pharmaciens ont reconnu que leur degré de confiance à l'égard de leurs connaissances sur la FA et les AcOD constituait un obstacle à la prescription de ces médicaments, et ils ont dit préférer consulter un médecin avant d'instaurer une AcO.
• la prescription d'un traitement préventif de l'AVc par les pharmaciens communautaires pourrait être un moyen de pallier les lacunes actuelles en matière de traitement; cela requiert toutefois l'établissement d'un cadre de collaboration avec les médecins et la mise en place d'une formation adéquate sur les recommandations des lignes directrices en matière d'AcO.
Original research Original research history (i.e., discharge summaries) and almost a third to review imaging. The use of Netcare for medical history was more frequent among pharmacists with APA status compared to those without (61% versus 46%, p = 0.009). In terms of interaction with physicians, the most common method was through fax (75%), and pharmacists with APA reported working together with physicians in a defined team more often than pharmacists without APA (38% versus 19%, p = 0.02).
Responses to case scenarios
The case scenarios and responses are shown in Table 2 . While the majority of pharmacists were able to identify patients who were eligible for stroke prevention therapy, there was difficulty in interpreting a patient (scenario 3) who would be high risk for bleeding. Pharmacists were not familiar with the appropriate antithrombotic agent to use, particularly when aspirin was applicable (scenario 2), and over half would initiate a drug other than warfarin for valvular AF (scenario 4). There was no difference in antithrombotic selection according to APA status. Univariate predictors of knowledge were practice setting (p = 0.03), interaction with physician (p = 0.02), percent time performing patient care services (p = 0.01) and DOAC self-efficacy (confidence in ability to extend, adapt, initiate or alter DOAC, p = 0.01). After multivariable analysis, the only significant predictors of knowledge were interaction with physicians (p = 0.04) and DOAC self-efficacy (p = 0.02).
Barriers to prescribing OAC
Pharmacists were asked to provide reasons they might choose warfarin or DOAC in the case scenarios where OAC was indicated. Cost of therapy (81%) and absence of special authorization (49%) were the most common reasons for Scenario 2: the patient is a 63-year-old woman. she lives at home with her husband; she is cognitively intact (as is her husband) and is fully independent and active for her age. Medical history includes myocardial infarction 4 years ago, with no residual deficits, and paroxysmal atrial fibrillation. current medications include ramipril 5 mg daily, atorvastatin 20 mg daily and atenolol 50 mg daily. she recalled taking aspirin in the past but stopped on her own years ago. the patient looks well for her age. blood pressure is 138/75; pulse is 83 but irregularly irregular. All laboratory work, including complete blood count, electrolytes, urea, creatinine and tsH, is normal. ecg confirms atrial fibrillation at 80 beats per minute and is also consistent with an old posterior myocardial infarction (but is otherwise unremarkable). echocardiogram also shows atrial fibrillation and mildly decreased posterior wall motion but is otherwise unremarkable (normal chamber sizes, normal systolic function and no valvular abnormalities). Scenario 3: the patient is a 64-year-old man. He lives at home with his wife; he is cognitively intact (as is his wife) and is fully independent and active for his age. Medical history includes permanent atrial fibrillation, significant bleeding after dental procedures on 2 occasions and abnormal liver function. Despite efforts made to persuade him to curtail his ongoing alcohol use, he reports drinking 3 to 4 drinks per day. the patient looks well for his age. blood pressure is 138/75; pulse is 83 but irregularly irregular. All laboratory work, including complete blood count, electrolytes, urea, creatinine and tsH, is normal, except his Alt is 100 and Inr is 1.3. ecg confirms atrial fibrillation at 80 beats per minute but is otherwise unremarkable. echocardiogram also shows atrial fibrillation but is otherwise unremarkable (normal chamber sizes, normal systolic function and no valvular abnormalities). Original research choosing warfarin, while fewer drug-drug/drugfood interactions (81%), lack of blood work (73%) and better safety profile in preventing brain bleeds (45%) were the most common reasons for choosing a DOAC. For pharmacists with APA, the most common barriers to prescribing OAC (warfarin or DOAC) were a preference for contacting the physician prior to prescribing (82%) and lack of sufficient knowledge about AF (51%, Figure 1) . Notably, the most common barrier for prescribing was the ability of the pharmacist to get hold of the physician (Figure 2 ).
Discussion
This is the first survey exploring the practicality of having pharmacists assessing and prescribing stroke prevention therapies in the management of patients with AF. Pharmacists demonstrated a good understanding of when stroke prophylaxis was appropriate in the case scenarios but had difficulty selecting the appropriate antithrombotic agent. Knowledge did not differ among pharmacists with or without APA, yet pharmacists with APA did indicate confidence in their understanding of AF as a major barrier to prescribing OAC therapy when indicated. Pharmacists expressed a preference for contacting the physician prior to prescribing but noted the inability to contact the physician as a major barrier. The most common reasons for choosing warfarin over DOAC were cost and need for special authorization, while pharmacists preferred DOAC over warfarin because of fewer interactions, safety profile and the lack of need for coagulation monitoring. The potential burden of AF-associated stroke is already a critical health issue that will only increase, since the prevalence of AF and stroke attributable to AF increases substantially with age; more than a quarter of Canadians over the age of 75 will develop AF. 27 Undertreatment is exposing AF patients to a significant risk of fatal or disabling strokes, particularly among patients who are asymptomatic (in whom AF is unrecognized) and those known to have AF but not receiving adequate OAC therapy. To better identify undertreated patients, studies of AF screening are beginning to emerge, including those involving community pharmacies. 28, 29 We recently conducted the first community-based integrated stroke screening program in pharmacies and found a 2.4% prevalence of newly diagnosed AF among participants ≥65 years; 60% had suboptimally controlled blood pressure, and 80% were at intermediate or high risk for developing diabetes. 29 Only a small fraction of patients in this study were started on OAC therapy despite high thromboembolic risk profiles, a finding consistent with a national screening 30 Even among patients with known AF, studies have shown underutilization of appropriate stroke prevention therapy. 11, 12 Closing the treatment gap in AF through pharmacist-based care is a promising approach to reducing stroke burden. There are increasing data to suggest the benefits of pharmacist involvement in the screening and management of cardiovascular conditions. [15] [16] [17] [18] [19] [20] [21] Effective management of warfarin for stroke prophylaxis in AF has been demonstrated in pharmacist-based anticoagulation clinics. 22, 23 In a recent randomized controlled study among patients with previous stroke, pharmacist prescribing of antihypertensive and lipid-lowering drugs led to significantly improved short-term risk factor control compared to a nurse-led disease management control group. 16 A similar positive impact has been demonstrated with risk modification among community pharmacists provided with a training program, including review of evidencebased practices and access to experts. 15 There are several reasons why pharmacists are well placed to deliver stroke prevention therapy in the community: 1) pharmacists are highly accessible, 31 which is important given the constraints on physicians' time with the management of 34, 35 ; and 3) pharmacists are exposed to a segment of the population that may not seek health care in traditional settings.
To allow community pharmacists to reach optimal knowledge regarding standards of practice and confidence in prescribing OAC in AF requires specific training in AF and frameworks for prescribing OAC, along with creating collaborative environments with local physicians. In our survey, most pharmacists with APA preferred to contact a physician prior to initiating OAC therapy, which in part may be explained by a lack of knowledge regarding AF and by the existing power asymmetries in health care, 36, 37 but also emphasizes the importance of establishing collaborative care pathways with physicians. It is not surprising that pharmacists are apprehensive about prescribing OAC therapy, since these decisions are complex even for patients and family physicians who are tasked to use/prescribe antithrombotic medications for a variety of reasons.
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Limitations Several limitations of this study warrant discussion. First, the response rate was moderate, despite using an incentive, as in other surveys. For comparison, a 2015 survey of Alberta pharmacists with a specialized diabetes practice had an 8.5% response rate. 39 However, unlike the diabetes survey, this sample was randomly drawn from the pharmacist population to reduce bias. Second, there may be a response bias, with only pharmacists who felt comfortable with this research topic responding to the survey-this makes our finding that most respondents felt the need for additional training on AF and OAC options all the more striking. Third, the survey was not validated.
Conclusion
This survey demonstrates that community pharmacists are able to identify AF patients requiring stroke prevention therapy, but additional knowledge of AF (including the selection of the appropriate antithrombotic therapy) is needed to enhance pharmacist confidence, as well as solutions for better physician contact/collaboration. Given the burden of AF-related stroke and the existence of effective treatment, efforts to optimize care delivery via community pharmacists should be pursued. Future studies are needed to identify strategies of pharmacist-based management that are effective and address current barriers to prescribing and optimal care. ■
